The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting a price directly in ...

In April, the FDA approved Pfizer's Beqvez, a one-time gene therapy for patients with hemophilia B. In July, the company reported positive results from a phase 3 trial of a gene therapy called ...

Earlier this year, FDA approved Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or ...

FDA approved the company's hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) in April. Pfizer noted in a press release that results for another arm of the BASIS trial in patients with ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment ...